The business manufactures and supplies high-performance containment and sterile transfer valves to the largest global pharmaceutical, bio-pharmaceutical and chemicals companies. Operating across Europe, Asia and North America, its patented technology is used in the development and manufacture of medicines and vaccines by the top 50 global pharmaceutical manufacturers, facilitating the safe transfer of highly-potent and sterile powders.
In January 2017 ChargePoint Technology secured investment from LDC to drive further international expansion. The investment by LDC, supporting Managing Director Chris Eccles and Sales Director Tony O’Sullivan in the buyout, will see LDC become a minority shareholder.
The business is capitalising on the strong and increasing demand for its solutions internationally, accelerating sales of its innovative AseptiSafe® Bio product, investing in the development of new products and on a targeted acquisition strategy to help it expand into adjacent sectors requiring containment and sterile transfer solutions.
In 2017 ChargePoint Technology was recognised for exceptional profit growth in The Sunday Times Profit Track 100, placing 27th on the list. This marks the company’s debut in the league table, which ranks Britain’s privately owned companies with the fastest-growing profits over three years.
In August 2018 ChargePoint Technology announced record financial results alongside plans for further international expansion. The business reported a 6% growth in revenue to £12.5m (2016: £11.7m) for the year to December 2017, citing a strong contribution from its US and India businesses.
LDC's investment and continuous support has turbocharged our growth and allowed us to set the wheels in motion on some exciting projects. We have lots of activity in the pipeline - almost too much! But we're looking forward to kickstarting our next phase of growth and enhancing our offering even further.Chris Eccles, CEO, ChargePoint